RESUMO
New Caledonia is a French territory located in the South Pacific Ocean. The prevalence rate of end-stage renal disease is nearly 3,000 per million inhabitants, making it one of the highest prevalence rates in the world. Preventing chronic kidney disease is a major public health issue. This article presents prevalence rates of chronic kidney disease (CKD) stages 3-5 for New Caledonia defined by a glomerular filtration rate estimated below 60 mL/min/1.73 m2. Estimation was assessed from data collected during two "Adult health barometer" surveys carried out in the general adult population. Therefore, our study assessed two prevalence rates: 7.8% [6.1; 10.1] and 5.3% [3.3; 8.5]. Those prevalence rates were two to four times higher than in mainland France which is consistent with the high prevalence rate of end stage renal disease treated in New Caledonia. Hence, CKD prevention is essential for New Caledonia.
La Nouvelle-Calédonie est une collectivité française dans l'océan Pacifique Sud. Le taux de prévalence de l'insuffisance rénale chronique terminale traitée s'élève à près de 3 000 par million d'habitants, soit un des taux de prévalence parmi les plus élevés au monde. Cet article présente pour la première fois les taux de prévalence de la maladie rénale chronique aux stades 3-5 pour la Nouvelle-Calédonie, définie par un débit de filtration glomérulaire estimé inférieur à 60 mL/min/1,73 m2. Ces résultats ont été estimés à partir des deux enquêtes « Baromètre santé adulte ¼ en population générale adulte. Notre étude a estimé des taux de prévalence de 7,8 % [6,1 ; 10,1] et de 5,3 % [3,3 ; 8,5]. Le taux de prévalence de la maladie rénale chronique serait donc deux à quatre fois plus élevé qu'en France métropolitaine. La prévention de la maladie rénale chronique est primordiale pour la Nouvelle-Calédonie.
Assuntos
Insuficiência Renal Crônica , Humanos , Prevalência , Nova Caledônia/epidemiologia , Insuficiência Renal Crônica/epidemiologia , Masculino , Pessoa de Meia-Idade , Feminino , Idoso , Adulto , Índice de Gravidade de DoençaRESUMO
New Caledonia is a French territory located in the South Pacific Ocean. The prevalence rate of end-stage renal disease is nearly 3,000 per million inhabitants, making it one of the highest prevalence rates in the world. Preventing chronic kidney disease is a major public health issue. This article presents prevalence rates of chronic kidney disease (CKD) stages 3-5 for New Caledonia defined by a glomerular filtration rate estimated below 60 mL/min/1.73 m2. Estimation was assessed from data collected during two "Adult health barometer" surveys carried out in the general adult population. Therefore, our study assessed two prevalence rates: 7.8% [6.1; 10.1] and 5.3% [3.3; 8.5]. Those prevalence rates were two to four times higher than in mainland France which is consistent with the high prevalence rate of end stage renal disease treated in New Caledonia. Hence, CKD prevention is essential for New Caledonia.
La Nouvelle-Calédonie est une collectivité française dans l'océan Pacifique Sud. Le taux de prévalence de l'insuffisance rénale chronique terminale traitée s'élève à près de 3 000 par million d'habitants, soit un des taux de prévalence parmi les plus élevés au monde. Cet article présente pour la première fois les taux de prévalence de la maladie rénale chronique aux stades 3-5 pour la Nouvelle-Calédonie, définie par un débit de filtration glomérulaire estimé inférieur à 60 mL/min/1,73 m2. Ces résultats ont été estimés à partir des deux enquêtes « Baromètre santé adulte ¼ en population générale adulte. Notre étude a estimé des taux de prévalence de 7,8 % [6,1 ; 10,1] et de 5,3 % [3,3 ; 8,5]. Le taux de prévalence de la maladie rénale chronique serait donc deux à quatre fois plus élevé qu'en France métropolitaine. La prévention de la maladie rénale chronique est primordiale pour la Nouvelle-Calédonie.
Assuntos
Insuficiência Renal Crônica , Humanos , Prevalência , Nova Caledônia/epidemiologia , Insuficiência Renal Crônica/epidemiologia , Masculino , Pessoa de Meia-Idade , Feminino , Idoso , Adulto , Índice de Gravidade de DoençaRESUMO
Objectives: This study aimed to determine the seroprevalence of immunoglobulin G antibodies targeting SARS-CoV-2 and other human coronaviruses after the first circulation of SARS-CoV-2 in New Caledonia, Pacific region. Methods: Blood samples were collected to detect the presence of SARS-CoV-2 immunoglobulin G antibodies. The sampling took place between July 2021 and July 2022 but was interrupted after the first circulation of SARS-CoV-2 (September 2021-March 2022) in New Caledonia. Data on ethnicity, age, gender, main residence, and anteriority of COVID-19 and vaccination were collected and analyzed. Results: A total of 747 participants, representative of New Caledonia's adult population, were included in the study. We found that 81% of the population had antibody responses to SARS-CoV-2 at the end of July 2022. The vaccination rate was 75%, whereas infections had affected 40% of the population. Individuals aged >45 years were significantly more vaccinated than those aged 18-44 years (80%, 95% confidence interval 74-84%). Oceanians were the most infected (50%, 95% confidence interval 42-57%). Conclusion: In New Caledonia, we show a high immunity rate (81%) after the first waves of SARS-CoV-2 circulation and the vaccination campaign. The analyses showed spatial heterogeneities in the infection rate across the territory and revealed that Oceanians were the most infected. Our study also highlighted high exposure of New Caledonia's population to other human coronaviruses.
